Dabigatran etexilate in people with atrial fibrillation

被引：3
|
作者：
Raju, Nina C. [1 ]
Hankey, Graeme J. [2 ]
机构：
[1] McMaster Univ, Hamilton Gen Hosp, Thrombosis Unit, Hamilton, ON L8L 2X2, Canada
[2] Univ Western Australia, Royal Perth Hosp, Dept Neurol, Perth, WA 6000, Australia
来源：
BRITISH MEDICAL JOURNAL | 2010年 / 341卷
关键词：
STROKE; ANTICOAGULATION; CLOPIDOGREL; ASPIRIN;
D O I：
10.1136/bmj.c3784
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] A real world data of dabigatran etexilate: multicenter registry of oral anticoagulants in nonvalvular atrial fibrillation
    Bunyamin Yavuz
    Mehmet Ayturk
    Selcuk Ozkan
    Mujgan Ozturk
    Caner Topaloglu
    Hakan Aksoy
    Cengiz Şabanoglu
    Ali Cevat Tanalp
    Kursat Dal
    Naim Ata
    Burcu Balam Yavuz
    Journal of Thrombosis and Thrombolysis, 2016, 42 : 399 - 404
  • [32] Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation
    Siddiqui, Fazeel M.
    Qureshi, Adnan I.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (08) : 1403 - 1411
  • [33] Dabigatran Etexilate A Review of its Use in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation
    Garnock-Jones, Karly P.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2011, 11 (01) : 57 - 72
  • [34] A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation
    Bin Yap, Lok
    Rusani, Beni Isman
    Umadevan, Dhanan
    Muhammad, Zulkeflee
    Hussin, Azlan
    Kaur, Surinder
    Omar, Razali
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2014, 38 (01) : 39 - 44
  • [35] Direct thrombin inhibitor dabigatran etexilate is approved in Europe for the prevention of stroke in patients with atrial fibrillation
    Skoda, Ondrej
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2011, 74 (05) : 591 - 592
  • [36] Dosage Adjustment of Dabigatran Etexilate Based on Creatinine Clearance in Patients With Cardioembolic Stroke or Atrial Fibrillation
    Matsuda, Shohei
    Imazu, Tomoko
    Kimura, Ryuji
    Nakamura, Mamoru
    Matsumoto, Atsushi
    Murakami, Teruo
    Maeda, Yorinobu
    THERAPEUTIC DRUG MONITORING, 2016, 38 (06) : 670 - 676
  • [37] A real world data of dabigatran etexilate: multicenter registry of oral anticoagulants in nonvalvular atrial fibrillation
    Yavuz, Bunyamin
    Ayturk, Mehmet
    Ozkan, Selcuk
    Ozturk, Mujgan
    Topaloglu, Caner
    Aksoy, Hakan
    Sabanoglu, Cengiz
    Tanalp, Ali Cevat
    Dal, Kursat
    Ata, Naim
    Yavuz, Burcu Balam
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2016, 42 (03) : 399 - 404
  • [38] Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan
    Chang, Chia-Hsien
    Yang, Yea-Huei Kao
    Chen, Jyh-Hong
    Lin, Li-Jen
    THROMBOSIS RESEARCH, 2014, 133 (05) : 782 - 789
  • [39] ANALYSIS OF COST-EFFECTIVENESS OF WARFARIN VS. DABIGATRAN ETEXILATE IN ATRIAL FIBRILLATION IN ECUADOR
    Penaherrera, E.
    Tettamanti, D.
    Aguirre, F.
    Puyol, L. F.
    Cardenas, E.
    Torres, G.
    Herran, S.
    VALUE IN HEALTH, 2015, 18 (07) : A830 - A830
  • [40] The assessment of anticoagulant activity to predict bleeding outcome in atrial fibrillation patients receiving dabigatran etexilate
    Chang, Yao-Ting
    Hu, Yu-Feng
    Liao, Jo-Nan
    Chern, Chang-Ming
    Lin, Yenn-Jiang
    Chang, Shih-Lin
    Wu, Cheng-Hsueh
    Sung, Shih-Hsien
    Wang, Kang-Ling
    Lu, Tse-Min
    Chao, Tze-Fan
    Lo, Li-Wei
    Hsu, Li-Chi
    Chung, Chih-Ping
    Chang, Peter M-H.
    Hsu, Wei-Hsuan
    Chiou, Chuen-Wang
    Chen, Shih-Ann
    BLOOD COAGULATION & FIBRINOLYSIS, 2016, 27 (04) : 389 - 395
12345